Osilodrostat Phosphate
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Osilodrostat Phosphate |
| DrugBank ID | DB11837 |
| Brand Names (EU) | Isturisa |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 98.19% |
Approved Indication (EMA)
Isturisa is indicated for the treatment of endogenous Cushing’s syndrome in adults.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | familial generalized lentiginosis | 98.19% | DL |
| 2 | acromelanosis | 98.05% | DL |
| 3 | congenital multiple café-au-lait macules-increased sister chromatid exchange syndrome | 98.05% | DL |
| 4 | gastrocutaneous syndrome | 97.96% | DL |
| 5 | leukonychia totalis-acanthosis-nigricans-like lesions-abnormal hair syndrome | 97.88% | DL |
| 6 | Moynahan syndrome | 97.77% | DL |
| 7 | rhabdoid tumor | 97.76% | DL |
| 8 | X-linked lymphoproliferative disease due to SH2D1A deficiency | 97.68% | DL |
| 9 | osteopathia striata-pigmentary dermopathy-white forelock syndrome | 97.66% | DL |
| 10 | peripheral nerve schwannoma | 97.51% | DL |
| 11 | schwannoma of twelfth cranial nerve | 97.40% | DL |
| 12 | sympathetic neurilemmoma | 97.37% | DL |
| 13 | microcystic/reticular schwannoma | 97.33% | DL |
| 14 | trigeminal schwannoma | 97.33% | DL |
| 15 | ACTH-dependent Cushing syndrome | 97.28% | DL |
| 16 | A20 haploinsufficiency | 97.20% | DL |
| 17 | benign neoplasm of adrenal gland | 97.12% | DL |
| 18 | immune dysregulation with inflammatory bowel disease | 96.96% | DL |
| 19 | Steel syndrome | 96.84% | DL |
| 20 | hemophagocytic syndrome associated with an infection | 96.47% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.